Be Bio: Clinical Stage Company Closes $92 Million (Series C) - Pulse 2.0

Retrieved on: 2025-01-26 01:17:57

Tags for this article:

Click the tags to see associated articles and topics

Be Bio: Clinical Stage Company Closes $92 Million (Series C) - Pulse 2.0. View article details on hiswai:

Excerpt

Be Biopharma, Inc. (Be Bio), a leader in B Cell Medicines (BCMs), announced the closing of its $92 million Series C financing.

Article found on: pulse2.com